We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will ...

Interim Management Statement covering Q3 2024/25 The Board of Directors of Rovsing A/S has today reviewed and approved the ...

Interim Management Statement covering Q3 2024/25 The Board of Directors of Rovsing A/S has today reviewed and approved the Interim Management Statement for the third quarter (1 January 2025- 31 March ...

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...

ABU DHABI – Agility Global PLC, a multi-business owner and operator and long-term investor, today reported Q1 2025 earnings ...

In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as ...

No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025Significant progress in the clinical pipeline, strengthening of organizational capabilities, and strategic ...

HHS Secretary Robert F. Kennedy Jr. and biopharmas will negotiate drug prices individually. Kennedy could "propose a rulemaking plan to impose MFN pricing" if no “significant” progress has been made.

Even though Danes are having historically few children these years, our population is increasing. One of the reasons is that ...

Despite historically low birth rates among Danes, the population is on the rise. A key reason is the influx of ...

Søstrene Grene has lofty ambitions: the Danish decoration chain wants to raise its turnover by 25 % this year, thanks to new ...

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in ...